SCM
HRTX icon

Sterling Capital Management’s Heron Therapeutics HRTX Stock Holding History

Sterling Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.7K Sell
4,627
-3,349
-42% -$3.88K ﹤0.01% 2832
2025
Q4 		$10.4K Sell
7,976
-1,438
-15% -$1.77K ﹤0.01% 2588
2025
Q3 		$11.9K Buy
9,414
+5,720
+155% +$9.07K ﹤0.01% 2396
2025
Q2 		$7.65K Buy
3,694
+1,848
+100% +$3.77K ﹤0.01% 2288
2025
Q1 		$4.06K Sell
1,846
-1,778
-49% -$3.45K ﹤0.01% 2268
2024
Q4 		$5.54K Buy
3,624
+3,275
+938% +$5.31K ﹤0.01% 2433
2024
Q3 		$695 Buy
+349
New +$833 ﹤0.01% 2718

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Sterling Capital Management's HRTX Position: Q1 2026 in Review

Sterling Capital Management reduced its Heron Therapeutics (HRTX) stake by 42% in Q1 2026, selling an estimated $3.88K and leaving 4,627 shares worth $3.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2832.

Sterling Capital Management first reported a position in HRTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $11.9K in Q3 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Sterling Capital Management held 4,627 shares of Heron Therapeutics worth $3.7K as of Q1 2026.
  • Sterling Capital Management sold 3,349 Heron Therapeutics shares in Q1 2026, an estimated $3.88K.
  • Heron Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2832 holding.
  • Sterling Capital Management first reported a position in Heron Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Heron Therapeutics position peaked at $11.9K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.